Literature DB >> 23884227

Three patients with glycogen storage disease type II and the mutational spectrum of GAA in Korean patients.

Hyung-Doo Park1, Dong Hwan Lee, Tae-Youn Choi, You Kyoung Lee, Soo-Youn Lee, Jong-Won Kim, Chang-Seok Ki, Yong-Wha Lee.   

Abstract

BACKGROUND: Glycogen storage disease II (GSD II) is caused by a deficiency of acid alpha-1,4-glucosidase and mutations in the GAA gene encoding this enzyme which are responsible for the pathogenesis of GSD II. Our goal was to determine the mutational spectrum in the GAA gene in Korean patients with GSD II.
METHODS: Three patients with GSD II were recruited based on clinical and biochemical findings. Alpha-1,4-glucosidase activity was determined and the GAA gene sequence was analyzed by PCR and sequencing. We also collected information about the genotypes of Korean patients with GSD II from the medical literature.
RESULTS: We identified six mutant alleles among the three GSD II patients: c.875A>G, c.1156C>T, c.1316T>A, c.1857C>G, and c2407_2412del7. c.1156C>T (Q386*) is a novel mutation. A comprehensive review of the literature revealed that a total of 29 mutant alleles, including 15 different mutations (10 missense, 3 deletion, and 2 nonsense mutations), were previously identified in 15 Korean GSD II patients. c.1316T>A (p.M439K) and c.1857C>G (p.S619R) were the most common mutations and accounted for 36.6% of the total mutant alleles.
CONCLUSIONS: We identified three GSD II patients and investigated the mutational spectrum in GAA in Korean patients with GSD II. Our results indicate that common mutations in the GAA gene vary according to ethnic background.

Entities:  

Keywords:  GAA; Glycogen storage disease II; Korean; novel mutation

Mesh:

Substances:

Year:  2013        PMID: 23884227

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  4 in total

1.  Clinical and GAA gene mutation analysis in mainland Chinese patients with late-onset Pompe disease: identifying c.2238G > C as the most common mutation.

Authors:  Xiao Liu; Zhaoxia Wang; Weina Jin; He Lv; Wei Zhang; Chengli Que; Yu Huang; Yun Yuan
Journal:  BMC Med Genet       Date:  2014-12-20       Impact factor: 2.103

2.  A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.

Authors:  Yasuyuki Fukuhara; Naoko Fuji; Narutoshi Yamazaki; Asami Hirakiyama; Tetsuharu Kamioka; Joo-Hyun Seo; Ryuichi Mashima; Motomichi Kosuga; Torayuki Okuyama
Journal:  Mol Genet Metab Rep       Date:  2017-10-31

3.  Long-Term Observation of the Safety and Effectiveness of Enzyme Replacement Therapy in Japanese Patients with Pompe Disease: Results From the Post-marketing Surveillance.

Authors:  Hitoshi Nagura; Jiro Hokugo; Kazuo Ueda
Journal:  Neurol Ther       Date:  2019-09-26

4.  Clinical and molecular characterization of Korean children with infantile and late-onset Pompe disease: 10 years of experience with enzyme replacement therapy at a single center.

Authors:  Min-Sun Kim; Ari Song; Minji Im; June Huh; I-Seok Kang; Jinyoung Song; Aram Yang; Jinsup Kim; Eun-Kyung Kwon; Eu-Jin Choi; Sun-Ju Han; Hyung-Doo Park; Sung Yoon Cho; Dong-Kyu Jin
Journal:  Korean J Pediatr       Date:  2018-10-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.